Australian journal of general practice · 2026
Age-related macular degeneration: Updates for general practitioners.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eiselen Carl, Long Marita, Chong Elaine W
Аннотация
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of legal blindness in Australians over 50 years, accounting for 60% of all blindness. AMD progresses from asymptomatic early and intermediate stages to late neovascular ('wet') or atrophic ('dry') forms that cause irreversible central vision loss. Age and family history are the strongest risk factors, while smoking, poor diet and cardiovascular disease are key modifiable contributors.
OBJECTIVE: To raise awareness of AMD in general practice and provide some advice on what general practitioners (GPs) can do to assist in early detection and prevention with an ageing population. GPs can examine the macula in at-risk adults, as well as encourage smoking cessation, a Mediterranean-style diet, regular exercise, and Age- Related Eye Disease Study 2 (AREDS2) supplementation for intermediate disease. Sudden distortion or vision loss requires urgent ophthalmology referral for possible neovascular AMD.
DISCUSSION: Intravitreal anti-VEGF (vascular endothelial growth factor) therapy remains the mainstay for wet AMD, while complement inhibitors show promise for geographic atrophy. Emerging gene, sustained-delivery and laser therapies might soon reduce treatment burden and improve adherence.
OBJECTIVE: To raise awareness of AMD in general practice and provide some advice on what general practitioners (GPs) can do to assist in early detection and prevention with an ageing population. GPs can examine the macula in at-risk adults, as well as encourage smoking cessation, a Mediterranean-style diet, regular exercise, and Age- Related Eye Disease Study 2 (AREDS2) supplementation for intermediate disease. Sudden distortion or vision loss requires urgent ophthalmology referral for possible neovascular AMD.
DISCUSSION: Intravitreal anti-VEGF (vascular endothelial growth factor) therapy remains the mainstay for wet AMD, while complement inhibitors show promise for geographic atrophy. Emerging gene, sustained-delivery and laser therapies might soon reduce treatment burden and improve adherence.